{"organizations": [], "uuid": "e074c6c95a2255c9db827c980dd0d7b620ce348b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/23/business-wire-innovus-pharma-expands-its-senior-management-with-the-addition-of-ryan-selhorn-cpa-as-its-vice-president-chief-financial.html", "country": "US", "domain_rank": 767, "title": "Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.053, "site_type": "news", "published": "2018-04-23T14:00:00.000+03:00", "replies_count": 0, "uuid": "e074c6c95a2255c9db827c980dd0d7b620ce348b"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/23/business-wire-innovus-pharma-expands-its-senior-management-with-the-addition-of-ryan-selhorn-cpa-as-its-vice-president-chief-financial.html", "ord_in_thread": 0, "title": "Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer", "locations": [], "entities": {"persons": [{"name": "ryan selhorn", "sentiment": "negative"}, {"name": "selhorn", "sentiment": "none"}], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "lead company’s financial and accounting operations", "sentiment": "neutral"}, {"name": "dare biosciences, inc.", "sentiment": "none"}, {"name": "innovus pharmaceuticals, inc.", "sentiment": "none"}, {"name": "company", "sentiment": "none"}, {"name": "signature analytics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Industry Veteran to Lead Company’s Financial and Accounting Operations into its Expanding Revenue Growth Stage\nSAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc. (\"Innovus Pharma\" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the hiring of Ryan Selhorn, CPA as its new Vice President, Chief Financial Officer effective as of April 27, 2018. Mr. Selhorn is an industry veteran whose financial and public accounting skills as well as his experience as the Chief Financial Officer consultant for Dare Biosciences, Inc. (NASDAQ: DARE). the Chief Financial Officer for MediciNova (NASDAQ: MNOV), and the Chief Financial Officer and Chief Accounting Officer for Signature Analytics provides the Company with the needed skill set to help the Company move into its next level of growth and revenues.\nFrom July 2013 to April 2018, Mr. Selhorn was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013, he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.\n“We are very excited to have Ryan join our growing team and we welcome him to Innovus Pharma,” said Innovus Pharma CEO, Dr. Bassam Damaj. “His finance, accounting and operation skills and public Nasdaq life science experience complement those of the executive management team and we look forward to his playing a major role in our efforts to grow the revenue of the Company in the next few quarters and increasing shareholder value during this period.\n“I am very happy to be joining the Innovus Pharma executive team,\" said Mr. Selhorn. “I believe I am joining the Company at a very important revenue growth stage and I am very excited about being part of the group that takes Innovus Pharma to the next stage in its development and growth cycle.”\nAbout Innovus Pharmaceuticals, Inc.\nHeadquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.\nFor more information, go to www.innovuspharma.com , www.zestra.com ; www.ejectdelay.com ; www.myvesele.com ; www.sensumplus.com ; www.myandroferti.com ; www.fluticare.com ; www.beyondhumantestosterone.com ; www.getbeyondhuman.com ; www.trybeyondhuman.com ; www.prostagorx.com ; www.allervarx.com ; www.apeaz.com ; www.diabasens ; and www.arthrivarx.com .\nInnovus Pharma's Forward-Looking Safe Harbor\nStatements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, successfully commercializing its products in the U.S. and internationally and to achieve its other development, commercialization, financial, up-listing and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180423005425/en/\nInnovus Pharma Investor Relations\nRandy Berholtz, +1 858 249 7865\nir@innovuspharma.com\nSource: Innovus Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.myvesele.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.myvesele.com&index=4&md5=cdb7e8ea8314216bd47630f5cea15e47", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.innovuspharma.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.innovuspharma.com&index=1&md5=6d518e790fe1073ea1dc3fba8f29906b", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zestra.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.zestra.com&index=2&md5=b83358eb4bb9d6650b9a9626308c7fc6", "https://www.businesswire.com/news/home/20180423005425/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.allervarx.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.allervarx.com&index=12&md5=285450ea56078ea86a3509cd8c8e70d4", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arthrivarx.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.arthrivarx.com&index=15&md5=9b0cbb345772ba56d9118a4fe38ad291", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.prostagorx.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.prostagorx.com&index=11&md5=81aae238ab27dff0f139cc9a244d598f", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.fluticare.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.fluticare.com&index=7&md5=53c07c3ef946c1dd786077ea0cbc583d", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sensumplus.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.sensumplus.com&index=5&md5=2492b6a849a91d2b1945e1a5564696e4", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.diabasens&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.diabasens&index=14&md5=8444e289da52cf42664b4df7de227f88", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.apeaz.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.apeaz.com&index=13&md5=37337a52d9cf1fcba31b8c89190bb3ad", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ejectdelay.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.ejectdelay.com&index=3&md5=264aedb7eafd797a32fcd96f6a05d65b", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.trybeyondhuman.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.trybeyondhuman.com&index=10&md5=2bb09ca162256c79aea6946ccbb3cefb", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.beyondhumantestosterone.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.beyondhumantestosterone.com&index=8&md5=7fe09f89ed18082f20a82bf3e7fa5dc2", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.getbeyondhuman.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.getbeyondhuman.com&index=9&md5=7b111df24b8d8cb6e6f7ad5d4a7fa097", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.myandroferti.com&esheet=51792966&newsitemid=20180423005425&lan=en-US&anchor=www.myandroferti.com&index=6&md5=385bf7aedf7796f2e677c1c7571dc089"], "published": "2018-04-23T14:00:00.000+03:00", "crawled": "2018-04-23T14:38:27.000+03:00", "highlightTitle": ""}